Inhibición de Crecimiento de Tumores de Cáncer de Próstata en Hipertermia Magnética mediada por Nanopartículas en Estudios Preclínicos: una Revisión de Alcance

2021 ◽  
Author(s):  
◽  
J. A. Parada Peralta
Keyword(s):  
Prostate Cancer ◽  
Tumor Growth ◽  
Magnetic Nanoparticle ◽  
Magnetic Hyperthermia ◽  
Tumor Growth Inhibition ◽  
Tissue Penetration ◽  
Deep Tissue ◽  
Incidence And Mortality ◽  
Low Toxicity ◽  
The Relationship

Prostate Cancer is one of the major concern types of cancer among men with respect to incidence and mortality. One relatively recent therapy against it, provided by Nanomedicine, is Nanoparticle mediated Magnetic Hyperthermia, which consists on tumor heating when exposed to an Alternating Magnetic Field in order to inhibit tumor growth (around 42 °C) (and make tumor sensible to other therapies: synergia) or to cause cancer cell apoptosis (greater temperature than 42°C). This procedure has several advantages like deep-tissue-penetration, targeted heating, low toxicity by Nanoparticles, and others. To this treatment, some of the Magnetic Nanoparticle properties are fundamental to its success, principaly the size, morphology, etc. Here, therefore, the relationship between the size of the employed Nanoparticles and the Tumor Growth Inhibition that cause is reviewed when treating Prostate Cancer tumors on mice models by Magnetic Hyperthermia.

scholarly journals Role of Precision Oncology in Type II Endometrial and Prostate Cancers in the African Population: Global Cancer Genomics Disparities

2022 ◽  
Vol 23 (2) ◽  
pp. 628
Author(s):  
Rahaba Marima ◽  
Rodney Hull ◽  
Mandisa Mbeje ◽  
Thulo Molefi ◽  
Kgomotso Mathabe ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Endometrial Cancer ◽  
African Ancestry ◽  
African Population ◽  
Precision Oncology ◽  
Type Ii ◽  
Incidence And Mortality ◽  
Prostate Cancers ◽  
The Relationship

Precision oncology can be defined as molecular profiling of tumors to identify targetable alterations. Emerging research reports the high mortality rates associated with type II endometrial cancer in black women and with prostate cancer in men of African ancestry. The lack of adequate genetic reference information from the African genome is one of the major obstacles in exploring the benefits of precision oncology in the African context. Whilst external factors such as the geography, environment, health-care access and socio-economic status may contribute greatly towards the disparities observed in type II endometrial and prostate cancers in black populations compared to Caucasians, the contribution of African ancestry to the contribution of genetics to the etiology of these cancers cannot be ignored. Non-coding RNAs (ncRNAs) continue to emerge as important regulators of gene expression and the key molecular pathways involved in tumorigenesis. Particular attention is focused on activated/repressed genes and associated pathways, while the redundant pathways (pathways that have the same outcome or activate the same downstream effectors) are often ignored. However, comprehensive evidence to understand the relationship between type II endometrial cancer, prostate cancer and African ancestry remains poorly understood. The sub-Saharan African (SSA) region has both the highest incidence and mortality of both type II endometrial and prostate cancers. Understanding how the entire transcriptomic landscape of these two reproductive cancers is regulated by ncRNAs in an African cohort may help elucidate the relationship between race and pathological disparities of these two diseases. This review focuses on global disparities in medicine, PCa and ECa. The role of precision oncology in PCa and ECa in the African population will also be discussed.

SOX9 stands for a bio-marker for prostate cancer detection

2020 ◽  
Author(s):  
Hao Zi ◽  
Wen-Lin Tao ◽  
Lei Gao ◽  
Zhao-Hua Yu ◽  
Xiao-Dong Bai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Roc Curve ◽  
Operating Characteristic ◽  
Diagnostic Value ◽  
Quantitative Real Time Pcr ◽  
Optimal Cutoff ◽  
Qrt Pcr ◽  
Incidence And Mortality ◽  
The Relationship

Abstract Background Prostate cancer is one of common cancers around the world, and in our country the incidence and mortality of PCa are both increasing. More and more reports have revealed that SOX9 is involved in various human cancers. In this study, we aimed to explore the relationship between SOX9 expression and diagnostic value of PCa patients. Methods In this study, quantitative real-time PCR (qRT-PCR) was performed to determine the expression of SOX9 of the 131 PCa patients and 74 healthy volunteers. And receiver operating characteristic (ROC) curve was used to determine the diagnostic value of SOX9 for PCa patients. Results The results of qRT-PCR showed that the expression of serum SOX9 in PCa patients was higher than that in healthy controls (P < 0.05). And the expression of SOX9 was significantly associated with PSA (P = 0.001), differentiation (P = 0.000), and lymph node metastasis (P = 0.000). Besides, the area under the ROC curve (AUC) was 0.966 with the sensitivity of 93.2% and specificity of 87.8% respectively. The optimal cutoff value of SOX9 was 2.34. Conclusions Our results found that SOX9 is a novel oncogene for PCa, and may be a novel and effective biomarker for the diagnosis of patients with PCa.

A biodegradable fluorescent nanohybrid for photo-driven tumor diagnosis and tumor growth inhibition

Nanoscale ◽  
2018 ◽  
Vol 10 (40) ◽  
pp. 19082-19091 ◽  
Author(s):  
Rajendra Prasad ◽  
Deepak S. Chauhan ◽  
Amit S. Yadav ◽  
Janhavi Devrukhkar ◽  
Barkha Singh ◽  
...  
Keyword(s):  
Reactive Oxygen Species ◽  
Tumor Growth ◽  
Growth Inhibition ◽  
Tumor Growth Inhibition ◽  
Oxygen Species ◽  
Deep Tissue ◽  
On Demand ◽  
Cancer Cell Death ◽  
Successful Design ◽  
Fluorescent Carbon Dots

A successful design of a novel red fluorescent carbon dots liposomal nanopitchers for deep tissue visualization and on demand phototriggered combined cancer therapy. The laser irradiation produces heat and reactive oxygen species that cause cancer cell death and tumor growth inhibition.

scholarly journals The Use of Upconversion Nanoparticles in Prostate Cancer Photodynamic Therapy

Life ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 360
Author(s):  
Michał Osuchowski ◽  
Filip Osuchowski ◽  
Wojciech Latos ◽  
Aleksandra Kawczyk-Krupka
Keyword(s):  
Prostate Cancer ◽  
Photodynamic Therapy ◽  
Near Infrared ◽  
Diagnostic Methods ◽  
Infrared Light ◽  
Upconversion Nanoparticles ◽  
Tissue Penetration ◽  
Deep Tissue ◽  
Visible Wavelengths ◽  
Intense Research

Photodynamic Therapy (PDT) is a cancer treatment that uses light, a photosensitizer, and oxygen to destroy tumors. This article is a review of approaches to the treatment of prostate cancer applying upconversion nanoparticles (UCNPs). UCNPs have become a phenomenon that are rapidly gaining recognition in medicine. They have proven to be highly selective and specific and present a powerful tool in the diagnosis and treatment of prostate cancer. Prostate cancer is a huge health problem in Western countries. Its early detection can significantly improve patients’ prognosis, but currently used diagnostic methods leave much to be desired. Recently developed methodologies regarding UCNP research between the years 2021 and 2014 for prostate cancer PDT will also be discussed. Current limitations in PDT include tissue irradiation with visible wavelengths that have a short tissue penetration depth. PDT with the objectives to synthesize UCNPs composed of a lanthanide core with a coating of adsorbed dye that will generate fluorescence after excitation with near-infrared light to illuminate deep tissue is a subject of intense research in prostate cancer.

scholarly journals MR Guided Pulsed High Intensity Focused Ultrasound Enhancement of Docetaxel Combined with Radiotherapy for Prostate Cancer Treatment

2018 ◽  
Author(s):  
Lili Chen ◽  
Alan Pollack
Keyword(s):  
Prostate Cancer ◽  
Gene Therapy ◽  
Tumor Growth ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Tumor Growth Inhibition ◽  
Prostate Cancer Treatment ◽  
Ultrasound Enhancement ◽  
Enhance Tumor Growth

This project will determine whether (1) HIFU increases the cellular update of docetaxel in vivo, and (2) the increased uptake of docetaxel combined with RT will enhance tumor growth inhibition. We will determine the optimal HIFU parameters, quantify the update of docetaxel using a radioactive tritiated docetaxel and evaluate the efficacy of docetaxel+RT in inhibiting prostate tumor growth in vivo. This research has the potential to improve local control and may also have effects on distant microscopic disease by promoting immune response, which will also lay the foundation for other tumor models and studies on gene therapy and thrombolytic drugs.

Prostate cancer: Autologous immunotherapy optimized by indoleamine-2,3-dioxygenase (IDO)-inhibitor as immune-tolerance breaker

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 12509-12509
Author(s):  
E. M. Lasalvia-Prisco ◽  
E. Garcia-Giralt ◽  
S. Cucchi ◽  
J. Larrañaga ◽  
D. Wagner
Keyword(s):  
Prostate Cancer ◽  
Tumor Growth ◽  
Immune Tolerance ◽  
Performance Status ◽  
Tumor Growth Inhibition ◽  
Primary Tumors ◽  
Group Iii ◽  
Group I ◽  
Group Ii ◽  
Asco Meeting

12509 Background: In several peer review publications (Cancer Biol Ther 2003) our team has reported a procedure of cancer immunotherapy using an autologous thermostable hemoderivative vaccine (ATHV) with anti-progressive tumor effect in metastatic malignant disease from different primary tumors including prostate cancer. Last year (ASCO Meeting 2005) we have reported that the tolerance break for tumor associated antigens through the interference with CD4+CD25+ regulatory cells is a component of the mechanism of action of the ATHV antitumoral effect. Therefore, we have intended to optimize this autologous immunotherapy adding to the procedure different steps of immune-tolerance blockage selected due to their proven efficacy in pre-clinical models and their feasibility in the frame of ATHV technology. In this study we report the results in prostate cancer when the adjuvant step added was the translational knowledge the tolerance blockage by IDO-inhibition through 1-Methyl-Tryptophane or 1-MT (Munn DH et al J Exp Med 1999). Methods: Thirty metastasic prostate cancer patients, hormone and chemotherapy resistant, Performance Status ≤ 2 and PSA progressing serum level, were included in this institutional-IRB approved phase I/II trial. The patients were randomized in 3 groups submitted to 3 different treatments: I, only sympthomatic; II, the previously reported ATHV and III, ATHV + simultaneous s.c. 1-MT. Tumor size increase (tumor growth) measured according RECIST was registered in each case. Mean difference in the 3 groups was statistically assessed (Student’s t-test). Tryptophane to Kynurenine conversion was tested to assess IDO inhibition. Results: Tumor growth was significantly slower in Group II and III than in Group I (p<0.01 and p<0.005). Tumor growth was also significantly slower in Group III than in Group II (p<0.02). IDO-inhibition was confirmed only in Group III. No relevant toxicities were detected. Conclusions: These results support that additional tolerance break by IDO-inhibition optimizes the tumor growth inhibition through immunotherapy with an autologous thermostable hemoderivative vaccine. No significant financial relationships to disclose.

scholarly journals A targeted near-infrared nanoprobe for deep-tissue penetration and imaging of prostate cancer

2021 ◽  
Author(s):  
Mena Asha Krishnan ◽  
Kratika Yadav ◽  
Paul Roach ◽  
Venkatesh Chelvam
Keyword(s):  
Prostate Cancer ◽  
Near Infrared ◽  
Imaging Agent ◽  
Tissue Penetration ◽  
Deep Tissue

Deep tissue penetration of a NIR PSMA-QD655 imaging agent in a 3D prostate cancer platform has been achieved.

Sign in / Sign up

Export Citation Format

Share Document